Statistics for Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody

Total visits

views
Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody 587

Total visits per month

views
January 2024 1
February 2024 5
March 2024 1
April 2024 2
May 2024 3
June 2024 7
July 2024 0

File Visits

views
Segal_2017_results.pdf 613

Top country views

views
United States 277
China 113
United Kingdom 14
Germany 11
South Korea 11
Italy 10
Australia 8
Canada 8
Sweden 8
Taiwan 5
Ukraine 5
Netherlands 4
Russia 4
France 3
Spain 2
India 2
Malaysia 2
Belgium 1
Switzerland 1
Israel 1
Lebanon 1
Norway 1
Poland 1

Top city views

views
Wilmington 55
Beijing 32
Fairfield 30
Houston 22
Shanghai 20
Ann Arbor 18
Washington 15
Cambridge 13
Seoul 9
Kiez 8
Jacksonville 7
Stockholm 7
White Plains 7
Brisbane 6
Florence 5
Kiev 5
Lake Mary 5
Shenzhen 5
Southampton 4
Duncan 3
Foshan 3
Mount Laurel 3
Rockville 3
Saint Petersburg 3
Tacoma 3
Taipei 3
Taiyüan 3
Anaheim 2
Brooklyn 2
Burlington 2
Cixi 2
Kaohsiung City 2
Mississauga 2
Nanjing 2
Nanterre 2
New York 2
Norwalk 2
San Francisco 2
Storm Lake 2
Tokyo 2
Toronto 2
Turin 2
Vancouver 2
Wuhan 2
Alameda 1
Alexandria 1
Alicante 1
Beirut 1
Bengaluru 1
Cardiff 1
Chengdu 1
Colonia 1
Derby 1
Detroit 1
Farmingville 1
Fort Washington 1
Frankfurt am Main 1
Geneva 1
Guangzhou 1
Gunzenhausen 1
Gurgaon 1
Hangzhou 1
Harbin 1
Henryk 1
Hillsborough 1
Hürth 1
Indianapolis 1
Jerusalem 1
Kilburn 1
Kuala Lumpur 1
Leicester 1
Leiden 1
Lexington 1
Lincoln 1
Los Angeles 1
Louisville 1
Lowell 1
Mahwah 1
Milpitas 1
Minneapolis 1
Motala 1
Mountain View 1
Málaga 1
Naperville 1
Naples 1
New Haven 1
New Westminster 1
Newbury Park 1
Nijmegen 1
Niles 1
Oslo 1
Peterborough 1
Philadelphia 1
Raritan 1
Richmond 1
Rome 1
Rotterdam 1
Roubaix 1
Royal Oak 1
Royston 1